Oral News and Research

RSS

Janssen, Vertex to evaluate TMC435 and VX-135 in Phase 2 HCV study

Janssen Pharmaceuticals, Inc. today announced that it has entered into a non-exclusive collaboration with Vertex Pharmaceuticals Incorporated to evaluate in a Phase 2 study the safety and efficacy of an all-oral regimen for the treatment of hepatitis C (HCV).

2 Nov 2012

TransTech Pharma to complete TTP054 Phase 2 trial on type 2 diabetes

TransTech Pharma, Inc., announced today that recruitment of patients for its recently initiated, multi-center Phase 2 clinical trial of TTP054 in type 2 diabetics, is exceeding expectations with initial top line results available in early 2013. The 90-day proof of concept study is being conducted in type 2 diabetics not well controlled with approved oral anti-diabetic agents.

2 Nov 2012

Malarial drug shows promise in stopping breast cancer

A malarial drug is showing promise in stopping breast cancer before it starts, Mason researchers are discovering during a clinical trial.

2 Nov 2012

Acupuncture shows promise in head and neck patients with xerostomia

Acupuncture significantly relieves the symptoms of xerostomia, or dry mouth, compared with oral care education in patients who have undergone radical or adjuvant radiotherapy for head and neck cancer, indicate the results of a randomized crossover trial.

1 Nov 2012

Nisin may slow or prevent squamous cell head and neck cancers

Nisin, a common food preservative, may slow or stop squamous cell head and neck cancers, a University of Michigan study found.

1 Nov 2012

Advaxis updates preliminary data from ADXS-HPV Phase 2 trial on cervical cancer

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, updated preliminary data from an ongoing randomized 110 patient Phase 2 trial of ADXS-HPV being conducted in India in women with recurrent/refractory cervical cancer who have failed previous cytotoxic therapy.

1 Nov 2012

FibroGen announces presentation of FG-4592 Phase 2 data on anemia at ASN Kidney Week 2012

FibroGen, Inc., today announced that two abstracts relating to FG-4592, its oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) clinical candidate for the treatment of anemia in chronic kidney disease, have been accepted for oral and poster presentations at the American Society of Nephrology (ASN) Kidney Week 2012.

1 Nov 2012

Additional data from EnVivo’s EVP-6124 Phase 2b trial on AD presented at CTAD meeting

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, today presented pharmacokinetic and pharmacodynamic data along with the previously reported statistically significant clinical results from its Phase 2b clinical trial of EVP-6124, a novel alpha-7 agonist, in patients with Alzheimer's disease.

1 Nov 2012

Roundup: Dallas approves stipend for gay, unmarried employees; Federal judge says Milwaukee can raise retiree contribution

Dallas County will give a stipend to unmarried and gay employees who provide health care benefits to their partners. County commissioners approved the new program in a narrow 3-2 vote, which was split along party lines. Democratic commissioners hailed the move as a way to attract and retain talent, embrace the county's diversity and compete against private companies who already provide domestic partner benefits.

1 Nov 2012

Watson acquires Actavis

Watson Pharmaceuticals, Inc. today announced that it has completed the acquisition of the Actavis Group for EUR 4.25 billion.

1 Nov 2012

Hormone therapy increases risk of heart attack or dying in women with metabolic syndrome

A new analysis of the Women's Health Initiative (WHI) trials show that women who had metabolic syndrome before they started hormone therapy had a greatly increased risk of heart attack or dying of heart disease. Women who didn't have metabolic syndrome beforehand showed no increased risk.

31 Oct 2012

Symposium to discuss latest scientific and clinical advances in treating non-Hodgkins lymphoma

Fifty world-renowned experts in non-Hodgkins lymphoma will convene in New York in November to present the latest scientific and clinical advances in treating a "lost generation" of sufferers-children, young adults and adolescents.

31 Oct 2012

Orexo initiates OX51 Phase II trial in patients undergoing prostate biopsy

Swedish specialty pharmaceutical company Orexo today communicated the start of the dose finding study for OX51 in patients undergoing prostate biopsy.

31 Oct 2012

Poor fitting and inadequate support leading to ineffective use of hearing aids

Twenty per cent of hearing aid users in Norway use the equipment for only an hour each day. The reason is often poor fitting and inadequate support. Now all this could change.

30 Oct 2012

Array BioPharma first quarter 2013 revenue decreases to $15.8 million

Array BioPharma Inc. today reported results for the first quarter of its fiscal year ending June 30, 2013.

30 Oct 2012

Doxepin oral rinse relieves mouth pain from head and neck cancer treatment

30 Oct 2012

Antidepressant doxepin eases pain associated with oral mucositis

An oral rinse of the antidepressant doxepin significantly eased pain associated with oral mucositis in patients receiving radiation therapy for cancers of the head and neck, a study led by Mayo Clinic found. The findings were presented at the American Society for Radiation Oncology annual meeting in Boston.

29 Oct 2012

Researchers learn how E2-79 molecule destroys complexes that induce allergic responses

Researchers have learned how a man-made molecule destroys complexes that induce allergic responses - a discovery that could lead to the development of highly potent, rapidly acting interventions for a host of acute allergic reactions.

29 Oct 2012

GTx to continue enobosarm Phase III trials for muscle wasting in patients with NSCLC

GTx, Inc. today announced that a per protocol interim safety review on Friday, October 26, 2012, by an independent Data Safety Monitoring Board (DSMB) recommended that GTx continue clinical development as planned with its two pivotal Phase III trials of enobosarm (GTx-024) for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer.

29 Oct 2012

High worldwide drug-resistant TB figures are “worrying

The prevalence of resistance to second-line therapy among individuals with multi-drug resistant tuberculosis is high, show the results of a study conducted using data from eight countries worldwide.

26 Oct 2012

Oral News and Research

Janssen, Vertex to evaluate TMC435 and VX-135 in Phase 2 HCV study

TransTech Pharma to complete TTP054 Phase 2 trial on type 2 diabetes

Malarial drug shows promise in stopping breast cancer

Acupuncture shows promise in head and neck patients with xerostomia

Nisin may slow or prevent squamous cell head and neck cancers

Advaxis updates preliminary data from ADXS-HPV Phase 2 trial on cervical cancer

FibroGen announces presentation of FG-4592 Phase 2 data on anemia at ASN Kidney Week 2012

Additional data from EnVivo’s EVP-6124 Phase 2b trial on AD presented at CTAD meeting

Roundup: Dallas approves stipend for gay, unmarried employees; Federal judge says Milwaukee can raise retiree contribution

Watson acquires Actavis

Hormone therapy increases risk of heart attack or dying in women with metabolic syndrome

Symposium to discuss latest scientific and clinical advances in treating non-Hodgkins lymphoma

Orexo initiates OX51 Phase II trial in patients undergoing prostate biopsy

Poor fitting and inadequate support leading to ineffective use of hearing aids

Array BioPharma first quarter 2013 revenue decreases to $15.8 million

Doxepin oral rinse relieves mouth pain from head and neck cancer treatment

Antidepressant doxepin eases pain associated with oral mucositis

Researchers learn how E2-79 molecule destroys complexes that induce allergic responses

GTx to continue enobosarm Phase III trials for muscle wasting in patients with NSCLC

High worldwide drug-resistant TB figures are “worrying

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News